NCT06172751

TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 250 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.

Detailed description

Retrospective database analysis using TriNetX database to describe HES patient characteristics, journey, and disease burden.

Conditions

• Hypereosinophilic Syndrome (HES)

Interventions

Type	Name	Description
OTHER	no intervention	not applicable, this is an observational retrospective data analysis study; no interventions in the study
OTHER	no intervention	not applicable, this is an observational retrospective data analysis study; no interventions in the study

Timeline

• Start date: 2023-12-15
• Primary completion: 2024-04-26
• Completion: 2024-04-26
• First posted: 2023-12-15
• Last updated: 2025-02-12

Locations

1 site across 1 country: United States